AIM ImmunoTech
13 hedge funds and large institutions have $557K invested in AIM ImmunoTech in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
45% less capital invested
Capital invested by funds: $1.01M → $557K (-$454K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$13.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.66K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$221K |
| 2 |
VF
Virtu Financial
New York
|
-$10K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $263K | -$221K | -181 | -41% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $110K | +$3.66K | +3 | +3% |
|
3
BlackRock
New York
| $105K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $24K | +$13.4K | +11 | +85% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $17K | – | – | – |
|
6
Creative Planning
Overland Park,
Kansas
| $9K | – | – | – |
|
7
Northern Trust
Chicago,
Illinois
| $7K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $7K | +$3.66K | +3 | +60% |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $6K | +$6.1K | +5 | New |
|
|
OAM
10
Occidental Asset Management
Burlingame,
California
| $4K | – | – | – |
|
11
Invesco
Atlanta,
Georgia
| $3K | – | – | – |
|
|
WPW
12
Waldron Private Wealth
Bridgeville,
Pennsylvania
| $2K | – | – | – |
|
|
VF
13
Virtu Financial
New York
| – | -$10K | -7 | Closed |
|
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
AIM Hedge Fund Activity: Q3 2018 in Review
13 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2018, worth a combined $557K — down 45% from $1.01M a quarter earlier.
Fund positioning in AIM was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $13.4K. The largest seller was Sabby Management, cutting an estimated $221K.
- 13 institutional investors held AIM ImmunoTech (AIM) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $557K of AIM ImmunoTech stock for Q3 2018, down 45% quarter-over-quarter.
- 1 fund opened new AIM ImmunoTech positions in Q3 2018 and 1 closed out, a net change of 0 holders.
- The largest AIM ImmunoTech buyer in Q3 2018 was Citadel Advisors, an estimated $13.4K added.
- The largest AIM ImmunoTech seller in Q3 2018 was Sabby Management, an estimated $221K sold.
Based on aggregated 13F filings for Q3 2018.